The increased risk of venous thromboembolism and the use of third generation progestagens: Role of bias in observational research
Authors:
- Lothar A.J. HeinemannLHLothar A.J. Heinemann
- Kenneth D. MacRaeKMKenneth D. MacRae
- Rudolph BruppacherRBRudolph Bruppacher
- Walter O. SpitzerWSWalter O. Spitzer
- 1 July 1996
- journal article
- Published by Elsevier in Contraception
- Vol. 54 (1) , 5-13
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Third generation oral contraceptives and risk of myocardial infarction: an international case-control studyBMJ, 1996
- Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control studyBMJ, 1996
- Interim review of the transnational case-control study of oral contraceptives and health: approved protocol revisions through September 1995Pharmacoepidemiology and Drug Safety, 1996
- Risk of idiopathic cardiovascular death and rionfatal venous thromboembolism in women using oral contraceptives with differing progestagen componentsThe Lancet, 1995
- Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagenThe Lancet, 1995
- A multinational case-control study of cardiovascular disease and steroid hormone contraceptivesJournal of Clinical Epidemiology, 1995
- Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic diseaseThe Lancet, 1995
- Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control studyThe Lancet, 1995
- Oral contraceptives and cardiovascular disease: An epidemiologic overviewPharmacoepidemiology and Drug Safety, 1993
- Trinational case–control study of oral contraceptives and healthPharmacoepidemiology and Drug Safety, 1993